HCG703.50

Healthcare Global Enterprises Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISRAINBOWJLHLCORONAMARKSANSMETROPOLISPARKHOSPSMcap ₹10,123 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity5.564.490.980.98
Return on Assets1.531.380.580.58
Return on Capital Employed7.907.057.547.54
Return on Invested Capital7.468.5710.4010.32
Margins
EBITDA Margin17.2417.4218.3018.28
Operating Margin8.127.928.718.71
Incremental Operating Margin6.6614.16
Pretax Margin3.522.531.001.46
Net Income Margin2.162.200.891.27
Net Income to Common Margin2.522.000.540.87
FCF Margin5.174.872.162.16
Additional
Effective Tax Rate39.2114.4716.2617.67
Sustainable Growth Rate5.564.490.980.98
Incremental Operating Margin %6.6614.162.39
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.